Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion type Assertion NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_head.
- NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion description "[Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1?, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPAR? in SAT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_provenance.
- NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion evidence source_evidence_literature NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_provenance.
- NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion SIO_000772 21289232 NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_provenance.
- NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion wasDerivedFrom befree-20150227 NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_provenance.
- NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_assertion wasGeneratedBy ECO_0000203 NP503357.RAL21HXTLHPQD61DrV3cf7ZDlOsBnmd77NGSnfLz3HOFQ130_provenance.